Physiomics Share Discussion Threads

[jack4691] 05/10/2023 19:57

Whatever has happened to that Gizmogizmo Olde Farte ??? PLEASE, PLEASE, PLEASE, keep him entertained over here on the PYC bb. We do NOT want him over on the UKOG bb, a right lil Nuisance, Liar, Mike Foxtrot that he is !! 🤣

[davevt] 05/10/2023 18:56

Do you know what's shocking..Laura just pasted this. Ignoring the fact it's from March, at that time Jim would have known Merck had only spent 300k, so was openly lying..

'
We’ve been engaged with Merck for many years, even before I arrived in the Company. As you will recall shortly after my arrival in the Company in around December 2017 we signed our first umbrella agreement with Merck where they aspired to spend at least €500,000 with us annually. I’m proud to say that we’ve done at least that every year since then. It’s not guaranteed and yet they’ve come back for more on a regular basis.'

[davevt] 05/10/2023 18:54

Nope, deleted

[share14] 05/10/2023 15:52

Ah right so Merck used to spend 500k euro a year but they reduced that last year. And nobody knows what they'll spend this year.

Thanks for clarifying you're not stating that they'll spend 500k euros this year.

---

Just posted on lse, lets see if this post sticks around or whether Riddler et al get it removed so they can make believe Merck are going to spend 500k euro.

[mam fach] 05/10/2023 14:17

Been a pump and dump share for years.
Never lived up to the hype.IMHO

[share14] 05/10/2023 12:00

Neither do I, it's why I contacted the FCA as something very whiffy is going on. (I used to work in financial market regulation)

[davevt] 05/10/2023 11:43

It just got deleted from lse. I really don't understand the bias over there by the admin...

[share14] 05/10/2023 11:21

Solid rebuttal dave

[davevt] 05/10/2023 10:04

It's funny reading Stevenfrxups -'my two cents'...ill paste below with my reaction in brackets...

'Before anyone starts, it's not advice or a ramp, it's how i see things at this moment in time.

£2.5mln market cap with c.£800,000 cash (YES LOW MARKET CAP AND NICE CASH BECAUSE THEY JUST DECIMATED THE SHARE PRICE WITH A FUND RAISE)


5 new contracts plus recommenced Merck revenues, €500,000 annually (ONE NEW CUSTOMER, EVERYTHING ELSE WAS EXISTING CUSTOMERS)

Hired 3 new personal to drive the business forward
(SHOULDN'T THAT HAVE ALREADY BEEN HAPPENING? YOU'VE JUST RAMPED UP YOUR WAGE BILL)

Main points from the annual report below :

The Company is looking forward to a successful financial year 2024 during which it aims to achieve a new best ever level of total income, generated from its current core business and emerging biostatistics consulting offering.(YOU SAID THAT LAST YEAR..)

Device to measure blood counts

Feedback from clinicians suggests that enabling patients to undergo these diagnostic tests in a primary care or home setting would facilitate use of our tool and as such we are actively exploring opportunities to work with Beyond Blood.(TOOLS LIKE THIS ALREADY EXIST, WHY SHOULD ANY ONE NEED YOURS?)

Collaborations

we are open to and continue to explore other approaches including risk sharing and collaboration. An example of this includes the risk-sharing deal with ValiRx plc announced in February 2021 for which terms have been fully disclosed and which would be triggered by the receipt by ValiRx of licensing revenues related to VAL-201 (THAT'S YEARS OF UNPAID WORK THAT MAY NEVER COME TO FRUITION LIKE THE VAL DEAL)

Strategic aims

expand and diversify core consulting business both through repeat business and through the acquisition of new clients; (ER, DID YOU JUST SAY YOUR STRATEGIC AIM IS TO KEEP EXISTING CUSTOMERS AND GET NEW ONES? GENIUS..

· Supplement consulting revenues through grant funded projects, especially in the field of personalised medicine (CRUK, Innovate UK, NIHR etc); (*SUPPLEMENT*...BASICALLY TRY AND MAKE UP THE SHORT FALL IN BUSINESS WITH GRANTS)

· Expand business into related fields, starting with biostatistics. This will be the subject of further announcements later this calendar year;

· Develop new, complementary areas of business such as personalised medicine and other service offerings in drug discovery and development that can add long term value to the business. (YOU SAID YOU WERE ALREADY DOING THIS)

[share14] 04/10/2023 17:03

Happy to post about record revenues, strong pipelines, bla bla, then post a big loss and raise at 1p while claiming it's for expansion. Not exactly confidence inspiring is it.

Why exactly do those shareholders on lse keep going on about PYC as if it's a great investment after those losses and the share price being decimated. Day in day out, same old thing for years, it's deranged behaviour.

[davevt] 04/10/2023 14:43

end of the day, they knew revenues would be dire and record losses, so that's why they did the raise.

Claiming otherwise is just total b.s.

[davevt] 04/10/2023 14:41

Can't believe trench posting this..

'Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue'

Maybe he is new to shares, but literally every company posts a statement like this annually.

Not that it even means anything. They are hardly going to admit they may not be able to proceed as a going concern, are they 🤣

[thiopia] 04/10/2023 12:34

Interesting read :-

Pete joins us with experience working for a wide variety of life sciences businesses across R&D and commercial operations, read on to find out why he is excited to join Physiomics and where he sees the most potential!

Q: What attracted you to the role at Physiomics?

: “Having worked across the biopharma industry for many years, I’m acutely aware of the mounting pressures drug development companies are under. Both regulatory and market pressures are pushing these companies to adopt innovative solutions to accelerate and de-risk their R&D, whilst reducing costs. I feel that the solutions Physiomics offer through their proprietary technologies and mathematical modelling expertise makes the company well positioned to support this endeavour. It is this exciting opportunity to contribute to a more efficient and successful drug development process and the business’s potential for growth that attracted me to the role.”

Q: What do you see as Physiomics’ greatest strengths?

A: “A unique ability to listen and work collaboratively with our clients, leveraging deep technical and scientific expertise to deliver tailored solutions to their needs. The broad experience of the team allows us to help clients gain insight into not only their asset, but also how it compares to similar ones in development or on the market. These insights are often very powerful, allowing for informed and more precise decisions to be made across the R&D continuum.”

Q: What opportunities do you see for the company?

A: “I think Physiomics certainly has an exciting future. The business has invested significantly in developing expertise and IP around its core modelling offering, with very positive client feedback and a high percentage of repeat business. With these solid foundations now built, I see an opportunity not only to scale the core business, but to build adjacent offerings in areas such as biostatistics and expand into new indications. Additionally, with continued development of our personalised medicine tools there is also the potential to significantly improve the health outcomes of cancer patients prescribed already marketed medicines.”

Q: What are you most excited about in your new role?

A: “I’ve only been here a couple of weeks, but one thing that immediately struck me is the very high calibre of the team we have here, both in the form of their expertise, technical ability, but also the culture. This, along with the opportunity I see we as a business have in the market, is a powerful combo – this is what excites me!”

[davevt] 04/10/2023 11:16

I don't get how they are able to do that over there..

[davevt] 04/10/2023 08:45

So pyc is is moving from being inside Oxford science park, into one of those shared office spaces in didcot...

🤣

[davevt] 03/10/2023 20:06

Laura is actually comedy gold. We had an rns today mentioning the new Biostatician....and it dropped the share price 8%..

...and what does Laura do.? Keep posting the rns in the chat..

yes, I can only assume Laura wants to kill the share price, by reposting badly received rns's 🤣

[share14] 03/10/2023 12:47

Apparently Laura is going to by a load of shares. So that's either inciting some form of frontrunning or a ramp. Why would anyone post that they're going to buy a load of shares if they were serious about it as the price would just get bid up?

[share14] 03/10/2023 08:47

How many posts can Laura make in a day ffs? 6 posts by 8.30am, more than there are trades.

[terminator101] 03/10/2023 07:38

Oh dear. More mouths to feed huh. Are the gerbils beginning to understand the business model yet ? It's only been 2 decades of loss making lifestyle pish so far.